Teladoc Health, Inc.

NYSE:TDOC

Medical - Healthcare Information Services

Healthcare
$8.06 +2.57%

+$0.20 today

Market cap
$1.47B
Beta
2.14
P/E (TTM)
-8.1
EPS (TTM)
-$0.96
52W Low $4.40High $9.77

Volume 3.96M

Average 4.68M

TDOC Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Teladoc Health, Inc.NYSE: TDOC

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $304.9M fell 7.5% year over year, ahead of the -20.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 46.5% from the prior quarter. Over 3 fiscal years it compounded at -5.9% a year.

Context

  • Selling, general & admin amounted to 42.9% of revenue in FY2025, down 9.5 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 16 analysts of $1.24B (+14.4%) for the fiscal year ending Dec 2026, a step up from the -19.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$304.9M+46.5% QoQ
Last fiscal yearDec 2025
$1.09B-19.4% YoY
LTMMar 2026
$1.06B-20.1% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.5%-3.1%+4.4 pp
1 year-19.4%+14.4%+33.8 pp
3-year CAGR-5.9%+4.0%+9.9 pp
5-year CAGR+3.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
1.09B USD
Year-over-year change
-19.4%
4-year CAGR
-0.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How TDOC compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -20.1% is the lowest of 11, against a peer median of +3.1%.
  • Selling, general & admin amounts to 42.2% of revenue for TDOC, versus a peer median of 38.3%.
TDOC Competitors
Selling, General & Admin for TDOC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TDOCTeladoc Health, Inc.LTM Mar 2026$1.06B USD-20.1%-5.9%42.2%
NVCRNovoCure LimitedLTM Mar 2026$461.38M USD+6.1%+10.9%68.4%
OMCLOmnicell, Inc.LTM Mar 2026$408.57M USD+4.8%-5.6%33.4%
AZTAAzenta, Inc.LTM Sep 2026$256.31M USD+1.6%-2.9%41.2%
PGNYProgyny, Inc.LTM Jun 2026$209.96M USD+4.6%+15.0%16.0%
PHRPhreesia, Inc.LTM Apr 2026$180.27M USD-4.7%-8.0%36.4%
EVOEvotec SELTM Mar 2026€172.36M EUR-9.3%-7.5%23.1%
SDGRSchrödinger, Inc.LTM Sep 2026$130.84M USD-5.7%+3.9%48.6%
OMDAOmada HealthLTM Mar 2026$114.04M USD-1.0%+16.9%40.3%
IMNMImmunome, Inc.LTM Sep 2026$64.15M USD+52.3%+47.5%—
PHVSPharvaris N.V.LTM Sep 2026€61.14M EUR+31.2%+15.6%—
Peer median (excluding TDOC) —+3.1%+7.4%38.3%

Competitors are the stored peer set for TDOC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.03B2.41B2.6B2.57B2.53B
Cost of Revenue650.26M743.99M760.03M751.27M771.59M
Gross Profit1.38B1.66B1.84B1.82B1.76B
Gross Margin68.0%69.1%70.8%70.8%69.5%
Research & Development311.88M333.63M348.52M307.27M277.92M
Selling, General & Admin1.11B1.3B1.37B1.35B1.09B
Operating Expenses1.65B15.32B2.09B2.84B2.02B
Depreciation & Amortization207.57M209.93M254.11M240.51M363.12M
EBITDA(31.42M)(7.54M)43.61M31.72M147.3M
EBITDA Margin-1.5%-0.3%1.7%1.2%5.8%
Operating Income(265.63M)(13.65B)(248.55M)(1.02B)(262.96M)
Operating Margin-13.1%-567.3%-9.6%-39.7%-10.4%
Interest Income776K12.67M46.78M57.07M36.77M
Interest Expense81.14M21.94M22.28M23.8M19.71M
Other Income / Expenses(119.03M)(10.13M)28.95M27.23M27.43M
Income Before Tax(384.66M)(13.66B)(219.61M)(993.65M)(235.53M)
Pre-Tax Margin-18.9%-567.7%-8.4%-38.7%-9.3%
Income Tax Expense44.14M(3.81M)760K7.59M(35.21M)
Net Income(428.79M)(13.66B)(220.37M)(1B)(200.32M)
Net Margin-21.1%-567.5%-8.5%-39.0%-7.9%
EPS (Basic)(2.73)(84.60)(1.36)(5.87)(1.14)
EPS (Diluted)(2.73)(84.60)(1.34)(5.87)(1.14)
Weighted Avg Shares156.94M161.46M162.17M170.56M176.22M
Weighted Avg Shares (Diluted)156.94M161.46M164.58M170.56M176.22M

Teladoc Health, Inc.

NYSE:TDOC

Intrinsic Alpha fair value

Locked

Current Price

$8.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.